Committee Composition

  Audit Compensation and Management Development Nominating and Corporate Governance
Lewis T. "Rusty" Williams, M.D., Ph.D. Chairman of the Board      
Franklin M. Berger, CFA Committee Chair for Audit Committee   Member of Nominating and Corporate Governance Committee
Garry Nicholson Member of Audit Committee    
Sheila Gujrathi, M.D.   Committee Chair for Compensation and Management Development Committee  
Peder K. Jensen, M.D.   Member of Compensation and Management Development Committee Committee Chair for Nominating and Corporate Governance Committee
Mark D. McDade   Member of Compensation and Management Development Committee  
William R. Ringo Member of Audit Committee   Member of Nominating and Corporate Governance Committee

Mr. Ringo has served as a member of our board of directors since October 2014. Since June 2010, Mr. Ringo has served as a senior advisor to Barclays Healthcare Group. From April 2008 until his retirement in April 2010, Mr. Ringo was Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc., a public pharmaceutical company, and was responsible for guiding Pfizer’s overall strategic planning and business development activities. Prior to joining Pfizer, Mr. Ringo served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo served as President and Chief Executive Officer of Abgenix, Inc., a biotechnology company acquired by Amgen, Inc.  Prior to Abgenix, Mr. Ringo served for 28 years at Eli Lilly and Company in numerous executive roles, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. Following Mr. Ringo’s retirement from Eli Lilly in 2001, from March 2001 to December 2007, Mr. Ringo served on various boards of directors, including InterMune, Inc. where he served as the non-executive chairman of the board of directors after serving as interim Chief Executive Officer from June 2003 to September 2003. Mr. Ringo currently serves on the boards of directors of Assembly Biosciences, Inc., Dermira, Inc., Immune Design Corp., Mirati Therapeutics, Inc., and Sangamo BioSciences, Inc., each of which is a public biotechnology company.  Mr. Ringo also served on the board of directors of Onyx Pharmaceuticals, Inc. from February 2011 until its acquisition by Amgen in October 2013. Mr. Ringo received a B.S. in business administration and an M.B.A. from the University of Dayton.


Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member

FPRX (Common Stock)

Exchange
NASDAQ
Price
20.89
Change (%)
0.00
Volume
N/A

Data as of 4:00 PM ET on Thursday, December 14, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.